BILLERICA, MA / ACCESSWIRE / July 26, 2024 / OmniGuide Holdings, Inc. (OGH) is thrilled to announce the successful completion...
Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to...
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose...
Institutional investors include affiliates of Off the Chain Capital and Discovery Capital ManagementMINNEAPOLIS, July 26, 2024 (GLOBE NEWSWIRE) -- OneMedNet...
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the...
Presentation to feature Silo’s novel therapeutics for the underserved SARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc....
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis...
Scienture, Inc., a private branded and specialty pharmaceutical company, entered into a business combination with TRxADE Health Inc., in an all-stock transaction...
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced...
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics,...
CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical...
TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and...
If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive...
TEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) a clinical stage biotechnology company...
SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell...
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare...
Real-world data demonstrating vaccine effectiveness against mpox of up to 90% after two MVA-BN doses and a significant reduction of...
$8 million grant funds development of NXC-201 in relapsed/refractory AL AmyloidosisLOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Nexcella,...